Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure the patterns and changes in platelet reactivity, thrombotic status and endothelial function. The observed patterns and changes will be related with inflammatory status, myocardial injury and outcomes
Description: patterns and changes of platelet aggregation values assessed by light transmission aggregometry after arachidonic acid, adenosine diphosphate and thrombin receptor activating peptide stimuli
Measure: on-treatment platelet reactivity Time: early stage of disease (first 96 hours)Description: patterns and changes of platelet aggregation values assessed by light transmission aggregometry after arachidonic acid, adenosine diphosphate and thrombin receptor activating peptide stimuli
Measure: on-treatment platelet reactivity Time: mid stage of disease (96 hours - 14 days)Description: patterns and changes of platelet aggregation values assessed by light transmission aggregometry after arachidonic acid, adenosine diphosphate and thrombin receptor activating peptide stimuli
Measure: on-treatment platelet reactivity Time: late stage of disease (>14 days)Description: patterns and changes of the rate of apoptosis in HUVEC incubated with serum from patients enrolled in the study.
Measure: apoptosis rate in human umbilical vein endothelial cells (HUVEC) Time: early stage of disease (first 96 hours)Description: patterns and changes of the rate of apoptosis in HUVEC incubated with serum from patients enrolled in the study.
Measure: apoptosis rate in human umbilical vein endothelial cells (HUVEC) Time: mid stage of disease (96 hours - 14 days)Description: patterns and changes of intracellular level of NO in HUVEC incubated with serum from patients enrolled in the study.
Measure: Nitric oxide (NO) intracellular levels Time: late stage of disease (>14 days)Description: patterns and changes of intracellular level of NO in HUVEC incubated with serum from patients enrolled in the study.
Measure: Nitric oxide (NO) intracellular levels Time: early stage of disease (first 96 hours)Description: patterns and changes of intracellular level of NO in HUVEC incubated with serum from patients enrolled in the study.
Measure: Nitric oxide (NO) intracellular levels Time: mid stage of disease (96 hours - 14 days)Description: patterns and changes of ROS
Measure: reactive oxygen species (ROS) levels Time: early stage of disease (first 96 hours)Description: patterns and changes of ROS
Measure: reactive oxygen species (ROS) levels Time: mid stage of disease (96 hours - 14 days)Description: patterns and changes of ROS
Measure: reactive oxygen species (ROS) levels Time: late stage of disease (>14 days)Description: patterns and changes of the most important coagulation factors (i.e. tissue factor antigen pg/dL)
Measure: coagulation factors levels Time: early stage of disease (first 96 hours)Description: patterns and changes of the most important coagulation factors (i.e. tissue factor antigen pg/dL)
Measure: coagulation factors levels Time: mid stage of disease (96 hours - 14 days)Description: patterns and changes of the most important coagulation factors (i.e. tissue factor antigen pg/dL)
Measure: coagulation factors levels Time: late stage of disease (>14 days)Description: values of FEV1% as assessed by spirometry
Measure: respiratory function Time: 6-monthDescription: values of FEV1% as assessed by spirometry
Measure: respiratory function Time: 12-monthDescription: values of left ventricular ejection fraction as assessed by transthoracic echocardiogram
Measure: cardiac function Time: 6-monthDescription: values of left ventricular ejection fraction as assessed by transthoracic echocardiogram
Measure: cardiac function Time: 12-monthDescription: occurrence of death, myocardial infarction, stroke and other major adverse events
Measure: clinical outcome Time: 12-monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports